AXSM Stock Axsome Therapeutics (AXSM, $154.19) Moving Average Convergence Divergence (MACD) Histogram turned positive on December 23, 2025

GET DAILY SIGNALS

Get AI intraday signals

AXSM - Axsome Therapeutics

MACD signal

View

Odds of UP Trend

Price: $154.19

Daily change: -$0.51 (-0.33%)

Daily volume: 469.9K

Capitalization: $7.8B

Industry: Biotechnology

This is a Bullish indicator signaling AXSM's price could rise from here. Traders may explore going long the stock or buying call options. A.I. dvisor identified 49 similar cases where AXSM's MACD histogram became positive, and of them led to successful outcomes. Odds of Success:

AXSM's RSI Oscillator recovers from overbought zone

The 10-day RSI Indicator for AXSM moved out of overbought territory on December 01, 2025. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 41 instances where the indicator moved out of the overbought zone. In of the 41 cases the stock moved lower in the days that followed. This puts the odds of a move down at .

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AXSM declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

AXSM broke above its upper Bollinger Band on December 19, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on December 19, 2025. You may want to consider a long position or call options on AXSM as a result. In of 68 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for AXSM just turned positive on December 23, 2025. Looking at past instances where AXSM's MACD turned positive, the stock continued to rise in of 49 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AXSM advanced for three days, in of 298 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 246 cases where AXSM Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AXSM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (105.263) is normal, around the industry mean (26.864). P/E Ratio (0.000) is within average values for comparable stocks, (51.341). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.882). Dividend Yield (0.000) settles around the average of (0.049) among similar stocks. P/S Ratio (13.532) is also within normal values, averaging (312.120).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.